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LETTER TO THE EDITOR
Radiation Therapy Reduces Local Failure and Improves Overall Survival in sPNET
To the Editor: We applaud the study by Fangusaro et al. [1] on
the treatment of young patients with sPNET which continues to be
a challenging disease requiring multi-disciplinary management.
However, we fear that with the authors’ focus on intensive
chemotherapy and autologous transplant they have underestimated
the curative value of radiation therapy in this disease. It is true that
12/20 survivors (60%) did not receive radiation therapy and,
therefore, were spared the toxicity of this treatment. Unfortunately,
21/43 children enrolled on the trial died of progressive/recurrent
disease, and only 8 of these received radiation. Therefore, more than
60% of patients who died did not receive a potentially curative
treatment while another two patients (4.7%) died directly as a result
of their intensive chemotherapy regimen. This seems a high price to
pay in order to avoid the potential late toxicity of radiation therapy.
Previous studies support the benefit of radiation therapy in the
treatment of sPNET. The German HIT-SKK87 and HIT-SKK92
trials examined a cohort of 29 patients (all <38 months), and the
only factor on multivariate analysis that predicted overall and
progression-free survival was the use of radiation therapy [2]. The
Canadian pediatric brain tumor consortium reported on 49 patients
where both chemotherapy and radiation therapy predicted survival,
but again only the use of radiation was associated with increased
survival on multivariate analysis [3].
In addition, when looking at the patterns of failure analysis for
Head Start I and II, it appears that at minimum local radiation
therapy to the site of the primary tumor would have made a
significant difference. For instance in those with progressive/
recurrent disease 17/25 (68%) experienced ‘‘local only’’ failure; 23/
25 (92%) of all failures had a local component. This is in contrast to
CCG-921, which included much less intensive chemotherapy in
combination with local and cranial-spinal radiation, where the
5-year rate of ‘‘local only’’ failure was 22% and for any failure
involving the primary site was 42% [4]. The importance of radiation
treatment with any concern for residual disease left after surgical
resection is a fact that was also born out by both the French [5] and
German [6] infant medulloblastoma studies using chemotherapy
alone. In these reports, following gross-total resection without
evidence of metastases, there was impressive long-term event free
and overall survival. However, if there was any residual or
metastatic disease chemotherapy alone had significantly worse
prognosis with EFS of <50% with residual disease and <20% with
metastatic disease [5,6].
Certainly the use of any therapy with potential morbidity should
be approached cautiously. However, given the clear benefit of
radiation therapy and the fact that modern radiation treatment may
be given in a fashion to decrease doses to normal tissues
thus minimizing late sequalea of therapy [7–9], even in young
children [7], we question the omission of this therapy from sPNET
regimens, especially in those with any residual/metastatic disease or
at the time of progression.
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